Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Slides:

Advertisements

Similar presentations

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States David B. Seifer, M.D., Valerie.

Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C) Michael W. Pankhurst,

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis Anuja Dokras, M.D., Ph.D., Shari.

Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis Héctor F. Escobar-Morreale, M.D., Ph.D., Manuel Luque-Ramírez,

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Michal Youngster, M. D. , Valerie L. Ward, M. D. , M. P. H. , Emily A

Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome Anuja Dokras, M.D., Ph.D., Shailly Saini,

Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study Cem Celik, M.D., Nicel.

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D

Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with.

Ellen W. Freeman, Ph. D. , Clarisa R. Gracia, M. D. , Mary D

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant? H. Browne, A. Armstrong,

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Epidemiology and Adverse Cardiovascular Disease (CVD) Risk Profile of Polycystic Ovarian Syndrome (PCOS): The Kaiser Permanente Polycystic Ovarian Syndrome.

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Parasitic myomas after laparoscopic myomectomy: case report

Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced.

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Ovulation induction in women with polycystic ovary syndrome

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Increased secretion of amylin in women with polycystic ovary syndrome

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Antoni J. Duleba, M.D., Ibrahim M. Ahmed, M.D. Fertility and Sterility

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial Antoni J. Duleba, M.D.,

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Fertility and Sterility: an evaluation

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Sedigheh Borna, M.D., Azita Nasery, M.D. Fertility and Sterility

Impact of subclinical hypothyroidism in women with recurrent early pregnancy loss Lia A. Bernardi, M.D., Ronald N. Cohen, M.D., Mary D. Stephenson, M.D.,

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions Kristen Farrell, M.S.,

Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome Yuwen Wu, M.D., Jianhua Zhang,

Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration Nicolas.

Current evaluation of amenorrhea

Inappropriate gonadotropin secretion in polycystic ovary syndrome

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Serum anti-Mullerian hormone dynamics during stimulated cycles by aromatase inhibitor anastrozole and clomiphene citrate in women with infertility H.-H.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Increased risk of depressive disorders in women with polycystic ovary syndrome Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,

Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis

Serum anti-müllerian hormone levels in women with secondary amenorrhea

Recurrence of ovarian torsion in a multiple pregnancy: conservative management via transabdominal ultrasound–guided ovarian cyst aspiration Kathleen.

Enrico Carmina, M.D., Rogerio A Lobo, M.D. Fertility and Sterility

Presentation transcript:

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women with anovulatory polycystic ovary syndrome Ashraf I. Elmashad, M.D. Fertility and Sterility Volume 95, Issue 7, Pages 2342-2346.e1 (June 2011) DOI: 10.1016/j.fertnstert.2011.03.093 Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Plasma anti-Müllerian hormone (AMH) levels and three-dimensional power Doppler flow studies in women with polycystic ovary syndrome (PCOS) before and after treatment with laparoscopic ovarian drilling (LOD). There was a significant reduction both in the plasma levels of AMH and ovarian stomal power Doppler flow indices after LOD in the PCOS group and remained low at 3- and 6-month follow-up. VI = vascularization index; VFI = vascularization flow index. Fertility and Sterility 2011 95, 2342-2346.e1DOI: (10.1016/j.fertnstert.2011.03.093) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Correlation between plasma anti-Müllerian hormone (in nanograms per milliliter) and both plasma T level (nanomoles per liter) and ovarian volume (milliliter) in polycystic ovary syndrome (PCOS) group. There was a significant positive correlation between plasma anti-Müllerian hormone and both T concentrations (r = 0.973, P<.001) and ovarian volume (r = 0.514, P=.016). Fertility and Sterility 2011 95, 2342-2346.e1DOI: (10.1016/j.fertnstert.2011.03.093) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions